The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 20, 2022

Filed:

May. 14, 2019
Applicants:

Kings College London, London, GB;

The Trustees of Dartmouth College, Hanover, NH (US);

Inventor:

Randolph Noelle, Plainfield, NH (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C07K 14/705 (2006.01); C12N 15/62 (2006.01); C12N 5/10 (2006.01); C12N 15/12 (2006.01); G01N 33/53 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 39/39 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 39/39566 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/6851 (2017.08); C07K 16/2827 (2013.01); C07K 16/2878 (2013.01); C12N 15/113 (2013.01); C12N 15/1138 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/5152 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/55516 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01); C12N 2310/14 (2013.01); C12N 2710/10034 (2013.01); C12N 2710/10043 (2013.01); Y02A 50/30 (2018.01);
Abstract

The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring 'checkpoint' protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).


Find Patent Forward Citations

Loading…